Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

CAR T-cell therapy clinical trial debuts at KU Cancer Center

KU Cancer Center has launched an investigator-initiated trial designed to attack three different targets on cancer cells at once. “The Triple Threat” approach is designed to boost CAR T-cell therapy’s chances of destroying blood cancers.

September 05, 2025

Vol.51 No.32

Clinical Roundup

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Clinical Roundup

Mayo Clinic researchers link CAR T-cell aging to cancer relapse

The aging process known as senescence is a mechanism involved in the failure of CAR T-cell therapy, according to a study by researchers at the Mayo Clinic.

July 18, 2025

Vol.51 No.28

Clinical Roundup

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

Scientists at the Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus-driven lymphomas. The findings, published in the Journal of Medical Virology, demonstrate that these drugs, which work by blocking the activity of the PARP1 enzyme, can halt tumor growth by interfering with the EBV’s ability to activate key cancer-promoting genes.

July 11, 2025

Vol.51 No.27

Podcast

In The Headlines: George Weiner on the importance of patients’ stories

In last week’s issue of The Cancer Letter, the cover story featured Col. Susan Fondy, an Army veteran and stage 3 breast cancer survivor, who is now living with lymphedema. Fondy is now a lymphedema advocate, working to prevent further cuts to the already-sparse funding for the disease.

July 09, 2025

Vol.51 No.26

Drugs & Targets

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is no longer necessary to ensure that the benefits of these CAR T-cell immunotherapies outweigh their risks and to minimize the burden on the healthcare delivery system of complying with the REMS.

July 03, 2025

Vol.51 No.26

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

YOU MAY BE INTERESTED IN

CAR T-cell therapy clinical trial debuts at KU Cancer Center

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Mayo Clinic researchers link CAR T-cell aging to cancer relapse

PARP1 inhibitors halt EBV-driven lymphoma by disrupting a key cancer pathway, preclinical study finds

In The Headlines: George Weiner on the importance of patients’ stories

REMS for currently approved BCMA- and CD19-directed autologous CAR T-cell immunotherapies eliminated

Renew today!

Subscriber content

Never miss an issue!

Login